Advertisements



vTv Therapeutics Fails Late-Stage Alzheimer"s Study; Is There A Chance For A Comeback?

vTv Therapeutics Fails Late-Stage Alzheimer"s Study; Is There A Chance For A Comeback?.....»»

Category: topSource: seekingalphaApr 16th, 2018

Stifel Sees Challenging Road Ahead For vTv Therapeutics After Failed Alzheimer"s Trial

vTv Therapeutics Inc (NASDAQ: VTVT) announced Monday after the close that results from Part A of its late-stage study of an investigational medication to treat Alzheimer's disease did not m Latest Ratings for VTVT D.....»»

Category: blogSource: benzingaApr 10th, 2018

Gilead falls after late stage NASH study fails, competitor Intercept moves up

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 11th, 2019

Pill for postpartum depression by Cambridge"s Sage succeeds in late-stage trial

Sage Therapeutics, one of Cambridge's largest biotech firms, today reported that its pill to treat postpartum depression appears to have succeeded in a late-stage trial. In a study of 151 women suffering from the condition, those who were given ora.....»»

Category: topSource: bizjournalsJan 7th, 2019

J&J"s Esketamine Fails to Meet Endpoint in Phase III Study

J&J's (JNJ) late-stage candidate, esketamine nasal spray, fails to show sta.....»»

Category: dealsSource: nytSep 24th, 2018

Histogenics Slips Below $1 Threshold After Knee Cartilage Candidate Fails Late-Stage Study

Histogenics Corp (NASDAQ: HSGX) shares were losing more than half their market value Wednesday following the release of top-line data from the Phase 3 trial of Neocar read more.....»»

Category: blogSource: benzingaSep 5th, 2018

Why Investors Are Hyped for Tonix Pharma’s PTSD Late-Stage Trial

Tonix Pharma shares made a solid gain on Monday after the firm announced that it is beginning to enroll patients in its late-stage study of Tonmya for the treatment of post-traumatic stress disorder......»»

Category: blogSource: 247wallstMar 11th, 2019

Is Immunogen Done After This Ovarian Cancer Study?

ImmunoGen shares were halved on Friday after the firm reported late-stage results from its ovarian cancer study......»»

Category: blogSource: 247wallstMar 1st, 2019

Novavax Re-Enters Penny Stock Territory After Respiratory Disease Vaccine Flunks Late-Stage Trial

Novavax, Inc. (NASDAQ: NVAX) shares were trading at less than $1 Thursday following the release of late-stage study results for its investigational vaccine candidate ResVax. read more.....»»

Category: blogSource: benzingaFeb 28th, 2019

CRISPR Therapeutics Up as Dosing Starts in Thalassemia Study

CRISPR Therapeutics (CRSP) and partner Vertex start dosing of beta thalassemia patients in an early-stage study evaluating gene editing therapy, CTX001. Initiates enrollment in sickle cell disease study. .....»»

Category: smallbizSource: nytFeb 26th, 2019

AstraZeneca"s Brilinta Found To Alleviate Cardiovascular Risk In Late-Stage Study

AstraZeneca plc (NYSE: AZN) was saved from heartache after its heart disease drug Brilinta succeeded in a late-stage study, sending its shares higher Monday. read more.....»»

Category: blogSource: benzingaFeb 25th, 2019

Viking seen as possible Gilead target after NASH treatment fails in late-stage trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 12th, 2019

Gilead"s Failed NASH Drug Trial Drags Stock Lower

Gilead Sciences, Inc. (NASDAQ: GILD) is facing another setback, as its non-alcoholic steatohepatitis, or NASH, candidate Selonsertib flunked in a late-stage study. read more.....»»

Category: blogSource: benzingaFeb 12th, 2019

Gilead stock down nearly 4% as drug trial fizzles

Gilead Sciences Inc. shares fell 4% in the extended session Monday after the pharma company said a late-stage, placebo-controlled study des.....»»

Category: topSource: marketwatchFeb 11th, 2019

J&J"s Erleada Meets Both Primary Endpoints in Late-Stage Study

Zacks.....»»

Category: topSource: redinewsFeb 1st, 2019

J&J"s Erleada Meets Both Primary Endpoints in Late-Stage Study

Johnson & Johnson's (JNJ) Erleada improves survival in metastatic .....»»

Category: smallbizSource: nytJan 31st, 2019

Roche Halts Two Late-Stage Studies on Alzheimer"s Candidate

Zacks.....»»

Category: topSource: redinewsJan 30th, 2019

The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoporosis Drug Study

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 22) Veracyte Inc (N.....»»

Category: earningsSource: benzingaJan 23rd, 2019

The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoporosis Drug Study

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 22) read more.....»»

Category: blogSource: benzingaJan 23rd, 2019

Biogen Begins Improved Dosing Regimen on Tysabri in Phase III

Biogen (BIIB) commences enrollment in late-stage study to evaluate an expanded interval dosing of its MS drug.....»»

Category: personnelSource: nytJan 4th, 2019

Why Cara Therapeutics Is One of Wednesday’s Big Winners

Cara Therapeutics shares jumped on Wednesday after the firm announced a key update in its late-stage chronic kidney disease trial......»»

Category: blogSource: 247wallstJan 2nd, 2019